Who are PF-07871987 Influenza saRNA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): adjuvanted Arepanrix, Quadrivalent influenza modRNA vaccine, Qiv, Anti-H1N1v Vaccine, Fluad alone, FluMist Quadrivalent (2017-2018).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pf-07871987-influenza-sarna.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

PF-07871987 Influenza saRNA — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PF-07871987 Influenza saRNA (pf-07871987-influenza-sarna) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RNA-based therapeutic. Area: Infectious Disease.

marketed RNA-based therapeutic influenza virus Infectious Disease Live · refreshed every 30 min

Target snapshot

PF-07871987 Influenza saRNA (pf-07871987-influenza-sarna) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PF-07871987 Influenza saRNA TARGET	pf-07871987-influenza-sarna	Pfizer	marketed	RNA-based therapeutic	influenza virus
adjuvanted Arepanrix	adjuvanted Arepanrix	University of British Columbia	marketed	Adjuvanted inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
Quadrivalent influenza modRNA vaccine	quadrivalent-influenza-modrna-vaccine	Pfizer	marketed	Vaccine	Influenza virus
Qiv	qiv	Pfizer	marketed	Inactivated vaccine	Influenza viruses
Anti-H1N1v Vaccine	Anti-H1N1v Vaccine	Institut National de la Santé Et de la Recherche Médicale, France	marketed	Inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
Fluad alone	Fluad alone	Korea University Guro Hospital	marketed	Inactivated influenza vaccine with adjuvant	Influenza virus hemagglutinin and neuraminidase antigens; MF59 acts as immunological adjuvant
FluMist Quadrivalent (2017-2018)	FluMist Quadrivalent (2017-2018)	MedImmune LLC	marketed	Live attenuated influenza vaccine (LAIV)	Influenza virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RNA-based therapeutic class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PF-07871987 Influenza saRNA — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-07871987-influenza-sarna. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab